J J Legos

Summary

Publications

  1. ncbi SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia
    J J Legos
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, PO Box 1539, 709 Swedeland Road, King of Prussia, PA 19406, USA
    Brain Res 892:70-7. 2001
  2. ncbi Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia
    F C Barone
    SmithKline Beecham Pharmaceuticals, Department of Cardiovascular Pharmacology, King of Prussia, PA 19406, USA
    Med Res Rev 21:129-45. 2001
  3. ncbi SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia
    F C Barone
    Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    J Pharmacol Exp Ther 296:312-21. 2001

Detail Information

Publications3

  1. ncbi SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia
    J J Legos
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, PO Box 1539, 709 Swedeland Road, King of Prussia, PA 19406, USA
    Brain Res 892:70-7. 2001
    ....
  2. ncbi Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia
    F C Barone
    SmithKline Beecham Pharmaceuticals, Department of Cardiovascular Pharmacology, King of Prussia, PA 19406, USA
    Med Res Rev 21:129-45. 2001
    ....
  3. ncbi SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia
    F C Barone
    Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    J Pharmacol Exp Ther 296:312-21. 2001
    ....